Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29329296 | 0.90 | SIGMAR1 (0.78) | SIGMAR1HRH3KCNJ1KCNH2 | |
| SCHEMBL29343050 | 0.83 | SIGMAR1 (0.63) | SIGMAR1DRD2HRH3HTR2BKCNA3 | |
| SCHEMBL18756761 | 0.82 | SIGMAR1 (0.71) | SIGMAR1 | |
| SCHEMBL30417282 | 0.81 | HRH3 (0.73) | SIGMAR1HRH3SLC6A4 | |
| SCHEMBL19043339 | 0.81 | HRH3 (0.73) | SIGMAR1HRH3SLC6A4 | |
| SCHEMBL8092283 | 0.81 | HRH3 (0.73) | SIGMAR1HRH3SLC6A4 | |
| SCHEMBL30671735 | 0.81 | SIGMAR1 (0.69) | SIGMAR1 | |
| SCHEMBL18704975 | 0.80 | SIGMAR1 (0.68) | SIGMAR1HRH3 | |
| SCHEMBL8111284 | 0.79 | HRH3 (0.81) | SIGMAR1DRD2HRH3SLC6A4 | |
| SCHEMBL29283196 | 0.78 | SIGMAR1 (0.59) | SIGMAR1DRD2HRH3HTR2BGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | SIGMAR1 3279/4885DRD2 2642/4885HRH3 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.